Study of Probuphine in Patients With Opioid Dependence

Opioid Dependency Clinical Trial

— PRO-809  

Official title:

An Open-label, Multi-center Extension Study of Probuphine in Patients With Opioid Dependence

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00772785
• Other study ID #: PRO-809
• Status: Terminated
• Phase: Phase 3
• Start date: September 2008
• Est. completion date: February 2009

Study information

• Verified date: June 2017
• Source: Titan Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine (buprenorphine implant) is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patients with opioid dependence. Patients who have completed at least 24 weeks of treatment in the Open-Label, Multi-Center Study of Probuphine in Patients with Opioid Dependence (PRO-807 Study), will be re-treated with Probuphine over an additional 24 weeks.

Description:

This is a 6-month, open-label, multi-center extension study. It is estimated that approximately 200 patients will be enrolled at approximately 25 sites in the United States (US). Following completion of either the PRO-807(NCT00630201) or PRO-808 studies, eligible patients will be implanted with Probuphine implants in the opposite arm for the PRO-809 study. Safety, BPN plasma levels, and efficacy measures will be collected during the 24-week treatment period.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 16
• Est. completion date: February 2009
• Est. primary completion date: February 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

Patients must meet the following eligibility criteria:

• Expected to complete 24 weeks of treatment in PRO-807 or PRO-808

• Voluntarily provide written informed consent prior to the conduct of any study-related procedures

• Deemed appropriate for entry into this re-treatment study by the Investigator

• Females of childbearing potential and fertile males must use a reliable means of contraception

Exclusion Criteria:

Patients are not eligible for enrollment if any of the following criteria are met:

• Presence of aspartate aminotransferase (AST) levels = 3 X upper limit of normal and/or alanine aminotransferase (ALT) levels = 3 X upper limit of normal and/or total bilirubin = 1.5 X upper limit of normal and/or creatinine = 1.5 X upper limit of normal, measured at the time of the Week 20 Visit for the previous trial (PRO-807 or PRO-808), or any time less than 5 weeks prior to the Implant Visit.

• Current diagnosis of chronic pain requiring opioids for treatment

• Pregnant or lactating females

• Current use of agents metabolized through cytochrome P450 3A4 (CYP 3A4) such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), and protease inhibitors (e.g., ritonavir, indinavir, and saquinavir)

• Current history of coagulopathy and anti-coagulant therapy (such as warfarin)

• Current use of benzodiazepines other than physician prescribed use

• Significant medical or psychiatric symptoms, cognitive impairment, or other factors which in the opinion of the Investigator, would preclude compliance with the protocol, patient safety, adequate cooperation in the study, or obtaining informed consent

• Concurrent medical conditions (such as severe respiratory insufficiency) that may prevent the patient from safely participating in study; and/or any pending legal action that could prohibit participation and/or compliance in the study

Related Conditions & MeSH terms

• Opioid Dependency
• Opioid-Related Disorders

Intervention

Drug:
• Probuphine (buprenorphine implant)
Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants 6-month duration)

Locations

Country	Name	City	State
United States	Scientific Clinical Research, Inc.	North Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Titan Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of adverse events		24 WEEKS
Secondary	Plasma buprenorphine concentration		24 WEEKS